Traitement de la polyarthrite rhumatoïde par des médicaments antirhumatismaux conventionnels, ciblés et biologiques en cas de lésions hépatiques et de stéatose hépatique non alcoolique
Rheumatol Int. 2022 doi: 10.1007/s00296-022-05143-y
An increased incidence of liver diseases emphasizes greater caution in prescribing antirheumatic drugs, owing to their hepatotoxicity. However, drug-induced liver injury (DILI) in RA patients represents an aetiological and therapeutic challenge, due to the intertwining of inflammatory and metabolic elements mediated by IL-6 and TNF-α.